Healthcare Stocks

Vectivbio Holding AG Files For Mixed Shelf Of Up To $350 Million

  • January 28, 2023 09:24 AM AEDT | Reuters
 Vectivbio Holding AG Files For Mixed Shelf Of Up To $350 Million

287 Jan 27 (Reuters) - VectivBio Holding AG: * VECTIVBIO HOLDING AG FILES FOR MIXED SHELF OF UP TO $350 MILLION - SEC FILING Further company coverage:

Read More...

Altamira Therapeutics Provides Business Update

Altamira Therapeutics Provides Business Update

  • January 28, 2023 01:16 AM AEDT | Reuters

Jan 27 (Reuters) - Altamira Therapeutics Ltd: * ALTAMIRA THERAPEUTICS PROVIDES BUSINESS UPDATE * ALTAMIRA THERAPEUTICS LTD - RESTRUCTURING OF FIVET CONVERTIBLE LOAN INCLUDING EXTENSION OF MATURITY *

Read More...
Spark Therapeutics Enters Into Strategic Collaboration With Neurochase For Use Of Proprietary Delivery Technology For Cns Disorders

Spark Therapeutics Enters Into Strategic Collaboration With Neurochase For Use Of Proprietary Delivery Technology For Cns Disorders

  • January 28, 2023 01:15 AM AEDT | Reuters

Jan 27 (Reuters) - Roche Holding AG: * SPARK THERAPEUTICS ENTERS INTO STRATEGIC COLLABORATION WITH NEUROCHASE FOR USE OF PROPRIETARY DELIVERY TECHNOLOGY FOR CNS DISORDERS Source text for Eikon:

Read More...
Amarin Announces Vazkepa® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Amarin Announces Vazkepa® (Icosapent Ethyl) Approved By Medsafe In New Zealand

  • January 28, 2023 01:14 AM AEDT | Reuters

Jan 27 (Reuters) - Amarin Corporation PLC: * AMARIN ANNOUNCES VAZKEPA® (ICOSAPENT ETHYL) APPROVED BY MEDSAFE IN NEW ZEALAND * AMARIN - ACTIVELY ENGAGING WITH POTENTIAL COMMERCIALIZATION PARTNERS IN

Read More...
Parkway Life Real Estate Investment Trust Says Distribution Per Unit Grew 2.7% To 7.32 SG Cents For 2H 2022

Parkway Life Real Estate Investment Trust Says Distribution Per Unit Grew 2.7% To 7.32 SG Cents For 2H 2022

  • January 28, 2023 01:01 AM AEDT | Reuters

Jan 27 (Reuters) - Parkway Life Real Estate Investment Trust: * DISTRIBUTION PER UNIT GREW 2.7% TO 7.32 SG CENTS FOR 2H 2022 * FY NET PROPERTY INCOME S$121.9 MILLION VERSUS S$111.2 MILLION * FY GROSS

Read More...
Exclusive-EU may pay more for Pfizer COVID shots in return for lower volume

Exclusive-EU may pay more for Pfizer COVID shots in return for lower volume

  • January 27, 2023 11:54 PM AEDT | Reuters

By Maggie Fick (Reuters) - Brussels is discussing with Pfizer and BioNTech the possibility of reducing the up to 500 million COVID-19 vaccine doses the EU has committed to buy this year in return for

Read More...
Sol Gel's Pricing Of Reg Direct Offering Of 2.6 Mln Shares At $5 Per Share

Sol Gel's Pricing Of Reg Direct Offering Of 2.6 Mln Shares At $5 Per Share

  • January 27, 2023 11:37 PM AEDT | Reuters

Jan 27 (Reuters) - Sol Gel Technologies Ltd: * SOL-GEL ANNOUNCES AGGREGATE $22.8 MILLION CONCURRENT REGISTERED DIRECT AND PRIVATE PLACEMENT OFFERINGS * SOL GEL TECHNOLOGIES - PRICING OF REGISTERED

Read More...
Positive CHMP Opinion For Darolutamide With Docetaxel For Treatment Of Metastatic Hormone-Sensitive Prostate Cancer

Positive CHMP Opinion For Darolutamide With Docetaxel For Treatment Of Metastatic Hormone-Sensitive Prostate Cancer

  • January 27, 2023 11:11 PM AEDT | Reuters

Jan 27 (Reuters) - Orion Oyj: * POSITIVE CHMP OPINION FOR DAROLUTAMIDE IN COMBINATION WITH DOCETAXEL FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER * ORION OYJ - CHMP RECOMMENDATION

Read More...
Sol Gel Acquires Patidegib

Sol Gel Acquires Patidegib

  • January 27, 2023 11:10 PM AEDT | Reuters

Jan 27 (Reuters) - Sol Gel Technologies Ltd: * SOL GEL TECHNOLOGIES LTD - PHASE 3 STUDY EXPECTED TO INITIATE IN SECOND HALF OF 2023, WITH RESULTS EXPECTED BY END OF 2025 * SOL-GEL ACQUIRES PATIDEGIB,

Read More...
Creso Pharma Announces LOI For Abby And Finn And Restructuring Of Existing Debt

Creso Pharma Announces LOI For Abby And Finn And Restructuring Of Existing Debt

  • January 27, 2023 09:11 PM AEDT | Reuters

Jan 27 (Reuters) - Creso Pharma Ltd: * LOI FOR ABBY AND FINN AND RESTRUCTURING OF EXISTING DEBT * ENTERED INTO A NON BINDING LETTER OF INTENT TO ACQUIRE ASSETS OF ABBY AND FINN LLC * UPON COMPLETION,

Read More...
Philippines defiant, says won't cooperate with ICC investigation

Philippines defiant, says won't cooperate with ICC investigation

  • January 27, 2023 08:53 PM AEDT | Reuters

* Justice secretary says ICC cannot impose on Manila * Duterte's crackdown on drugs blamed for over 6,200 deaths * ICC had in 2021 suspended investigation at Manila's request * Marcos has previously

Read More...

Frequently Asked Questions

Given the fact that healthcare is a necessity, investing in healthcare stocks can be rewarding. However, to make good returns from these stocks, an investor should have sound knowledge about the sector and should be aware of the latest trends in the sector.

The standard checklist that one would run to find a good stock, holds true for screening healthcare stocks too. However, there are few aspects that are important to be considered for healthcare stocks. Well established pharmaceutical stocks with a good history of drug discovery and effective treatments typically have some sort of moat around them, thanks to their scale and financial wherewithal. However, new, and small companies with unique innovations or a strong product pipeline are also worth investigating, as they have a longer runway. Healthcare companies are able to pass on inflation-led input cost pressure, since people usually do not cut back on their healthcare expenses even during an inflationary environment. Companies that are able to maintain good profit margin are seen commanding valuation premiums in the market. Investors can also look for healthcare companies with strong patent portfolio, as patents can provide good price and competition protection for longer periods. Finally, before finalising any share, some of the fundamentals such as return on equity, revenue growth, net margin growth, management capabilities in terms of capital allocation, dividend pay-out should be considered.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK